AKT1 and breast cancer: In contrast, Bhowmik et al. demonstrated that estrogen receptor pathway activation in MCF7 breast cancer cells inhibits ERK, p38 MAPK, and PI3K/Akt signaling, decreasing NF-κB and MMP-9 expression, thereby exhibiting an anti-metastatic effect [121].